P053 | LONG-TERM EFFECTIVENESS AND SAFETY OF FREMANEZUMAB FOR MIGRAINE PREVENTION: 24-MONTH OUTCOMES FROM THE ITALIAN COHORT OF THE PEARL STUDY
Confinia Cephalalgica · 03.11.2026 · 36 (s1)
DOI: 10.4081/cc.2026.16009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Fremanezumab is a calcitonin gene-related peptide pathway monoclonal antibody approved for the prevention of episodic (EM) and chronic migraine (CM). In Italy, fremanezumab reimbursement is subject to Italian Medicines Agency criteria (≥8 monthly migraine days [MMD], a Migraine Disability Assessment [MIDAS] score of ≥11 before treatment and ≥3 prior preventive treatment failures). Here, we report effectiveness and safety of fremanezumab for migraine prevention in Italian participants enrolled in the observational, Phase 4 Pan-European Real Life (PEARL; EUPAS35111) study after 24 months of follow-up.
Methods
Eligible participants were adults with high-frequency EM (HFEM) and CM receiving monthly (225 mg) or quarterly (675 mg) fremanezumab in routine clinical practice. A mandatory ≥1 month treatment discontinuation period occurred following 12 months of continuous treatment. The primary endpoint was the proportion of participants achieving ≥50% reduction in MMD during the 6 months following fremanezumab initiation. Secondary endpoints included mean change from baseline in MMD at Months 1 and 24, and mean MIDAS scores over 24 months. Safety was assessed through adverse event (AE) reporting.
Results
This analysis included 354 participants (HFEM, n=125; CM, n=229) from 30 Italian centres (female, 82.2%; CM, 64.7%; baseline MMD, 15.6 days). In total, 61.9% (n=219/354) of participants achieved ≥50% reduction in MMD during the 6-month period after fremanezumab initiation. Mean change from baseline in MMD was sustained from Month 1 (total, –8.2; HFEM, –5.4; CM, –9.8) to Month 24 (total, –10.5; HFEM, –6.5; CM, –12.7). In participants with documented cessation and reinitiation, mean MIDAS scores decreased from 93.7 at baseline (HFEM, 67.8; CM, 107.8) to 22.0 at Month 12 after fremanezumab initiation (HFEM, 14.0; CM, 26.0), and from 37.5 at baseline of reinitiation (HFEM, 29.9; CM, 42.6) to 25.3 at Month 12 after reinitiation (HFEM, 11.7; CM, 31.5). Drug-related AEs were reported in 62/354 (17.5%) participants, with 2/354 (0.6%) reporting drug-related serious AEs and 4/354 (1.1%) reporting AEs that led to discontinuation.
Conclusions
These results underscore the long-term effectiveness and safety of fremanezumab for the preventive treatment of HFEM and CM and the importance of continued treatment now that treatment pauses are no longer mandated.
Zitieren
APA
(2026). P053 | LONG-TERM EFFECTIVENESS AND SAFETY OF FREMANEZUMAB FOR MIGRAINE PREVENTION: 24-MONTH OUTCOMES FROM THE ITALIAN COHORT OF THE PEARL STUDY. Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.16009
Vancouver
P053 | LONG-TERM EFFECTIVENESS AND SAFETY OF FREMANEZUMAB FOR MIGRAINE PREVENTION: 24-MONTH OUTCOMES FROM THE ITALIAN COHORT OF THE PEARL STUDY. Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.16009
BibTeX
@article{euvimed2026,
title = {P053 | LONG-TERM EFFECTIVENESS AND SAFETY OF FREMANEZUMAB FOR MIGRAINE PREVENTION: 24-MONTH OUTCOMES FROM THE ITALIAN COHORT OF THE PEARL STUDY},
journal = {Confinia Cephalalgica},
year = {2026},
volume = {36},
number = {s1},
doi = {10.4081/cc.2026.16009}
}
EUVIMED